Maria Palasis Founder of Lyra Therapeutics Backed byNorth Bridge Venture Partners & Growth EquityEd Anderson SourcesLyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) — 2020-01 Browse all founders · Browse investors
